A COMPARATIVE ANALYSIS OF EFFICACY AND SAFETY OF PREGABALIN VERSUS DULOXETINE IN MANAGING DIABETIC NEUROPATHY

K GUL; Y KHAN; M BILAL; AU KHAN; M SALMAN

doi:10.54112/pjicm.v5i02.126

Authors

K GUL Department of Medicine, Lady Reading Hospital Peshawar, Pakistan
Y KHAN Department of Medicine, Lady Reading Hospital Peshawar, Pakistan
M BILAL Department of Medicine, Lady Reading Hospital Peshawar, Pakistan
AU KHAN Department of Medicine, Khalifa Gulnawaz Teaching Hospital Bannu, Pakistan
M SALMAN Department of Medicine, Lady Reading Hospital Peshawar, Pakistan

DOI:

https://doi.org/10.54112/pjicm.v5i02.126

Keywords:

Diabetic Neuropathy, Pregabalin, Duloxetine, Efficacy, Safety

Abstract

Background: Diabetic neuropathy is a common complication of diabetes mellitus, often leading to significant morbidity and impaired quality of life. Pharmacological management includes agents such as pregabalin and duloxetine, but comparative evidence on their efficacy and safety remains limited in local populations. Objective: To compare the efficacy and safety of pregabalin versus duloxetine in the management of diabetic neuropathy at Lady Reading Hospital, Peshawar. Study Design: Randomized controlled trial. Setting: Department of Medicine, Lady Reading Hospital, Peshawar, Pakistan. Duration of Study: 05-December-2024 to 05-June-2025. Methods: A total of 160 patients aged 30–75 years with confirmed diabetes mellitus and clinically diagnosed diabetic neuropathy were randomly assigned to two equal groups. Group A received pregabalin (300 mg/day) and Group B received duloxetine (60 mg/day). Efficacy was evaluated by improvement in neuropathic symptoms and physical examination findings. Safety was assessed based on the occurrence of adverse events, including constipation, decreased appetite, and lethargy. Statistical analysis was performed using SPSS version 25, with chi-square and t-tests applied as appropriate; p-values <0.05 were considered statistically significant. Results: In the duloxetine group, 77.5% of patients achieved symptomatic improvement compared to 61.2% in the pregabalin group (p < 0.05). Adverse event profiles were comparable between the two groups. Pregabalin was associated with a higher incidence of lethargy (11.2%), while duloxetine had slightly more cases of constipation (7.5%), with no statistically significant difference (p > 0.05). Conclusion: Duloxetine demonstrated significantly greater efficacy than pregabalin in managing diabetic neuropathy, while both drugs exhibited similar safety profiles. Duloxetine may be considered a preferred option in this patient population.

References

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843

Pop-Busui R, Ang L, Boulton AJM, Feldman EL, Marcus RL, Mizokami-Stout K, et al. Diagnosis and treatment of painful diabetic peripheral neuropathy. Arlington (VA): American Diabetes Association; 2022. https://doi.org/10.2337/db2022-01

Rosenberger DC, Blechschmidt V, Timmerman H, Wolff A, Treede R-D. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm (Vienna). 2020;127(4):589-624. https://doi.org/10.1007/s00702-020-02145-7

Callaghan BC, Gallagher G, Fridman V, Feldman EL. Diabetic neuropathy: what does the future hold? Diabetologia. 2020;63(5):891-7. https://doi.org/10.1007/s00125-020-05085-9

Pang L, Lian X, Liu H, Zhang Y, Li Q, Cai Y, et al. Understanding diabetic neuropathy: focus on oxidative stress. Oxid Med Cell Longev. 2020;2020:9524635. https://doi.org/10.1155/2020/9524635

Papagno C. Memory deficits. In: Vallar G, Coslett HB, editors. The parietal lobe. Handbook of Clinical Neurology, vol. 151. Amsterdam: Elsevier; 2018. p. 377-393. https://doi.org/10.1016/B978-0-444-63622-5.00019-X

Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. https://doi.org/10.2337/dc16-2042

Sloan G, Alam U, Selvarajah D, Tesfaye S. The treatment of painful diabetic neuropathy. Curr Diabetes Rev. 2022;18(5):e070721194556. https://doi.org/10.2174/1573399817666210707112413

National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in non-specialist settings. NICE guideline [CG173]. London: NICE; 2013 [updated 2020; cited 2025 Aug 14]. Available from: https://www.nice.org.uk/guidance/cg173.

Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412-418. https://doi.org/10.2337/dc16-2641

Kinoshita J, Takahashi Y, Watabe AM, Utsunomiya K, Kato F. Impaired noradrenaline homeostasis in rats with painful diabetic neuropathy as a target of duloxetine analgesia. Mol Pain. 2013;9:59. https://doi.org/10.1186/1744-8069-9-59

Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidence and possible mechanisms. Curr Neuropharmacol. 2014;12(1):44-56. https://doi.org/10.2174/1570159X1201140117162802

Rakusa M, Marolt I, Stevic Z, Rebrina SV, Milenkovic T, Stepien A. Efficacy of pregabalin and duloxetine in patients with painful diabetic peripheral neuropathy (PDPN): a multi-centre phase IV clinical trial—BLOSSOM. Pharmaceuticals. 2023;16(7):1017. https://doi.org/10.3390/ph16071017

Nagra MA, Hanif M, Nisa SU, Hafeez A, Ahmed M, Bashir B. Comparison of efficacy of pregabalin with duloxetine in the management of patients with painful diabetic neuropathy. Prof Med J. 2023;30(05):630-636. https://doi.org/10.29309/TPMJ/2023.30.05.6721

Shahid W, Kumar R, Shaikh A, Kumar S, Jameel R, Fareed S. Comparison of the efficacy of duloxetine and pregabalin in pain relief associated with diabetic neuropathy. Cureus. 2019;11(7):e5293. https://doi.org/10.7759/cureus.5293

Warrier K, Kavyshree AC, Vishnu K, Ayyappanavar S. A comparative study of efficacy and safety of pregabalin with methylcobalamin versus duloxetine with methylcobalamin in diabetic peripheral neuropathy patients with type 2 diabetes mellitus. J Popul Ther Clin Pharmacol. 2025;32(4):366-375. https://doi.org/10.53555/z2wgh543

Shah I, Ahmad W, Islam M, Jan B, Haq EU, Mahmood J, et al. A prospective observational study comparing the efficacy and safety of duloxetine and pregabalin in diabetic peripheral neuropathic pain. Cureus. 2022;14(9):e28683. https://doi.org/10.7759/cureus.28683

Gulzar HR, Zahoor N, Zahoor A, Saghir H, Tariq M, Bibi A, et al. Comparison of the efficacy of duloxetine versus pregabalin for pain relief of neuropathy in diabetics. Pak J Med Dent. 2024;13(1):5-10. https://doi.org/10.36283/PJMD13-1/003